Lee Wazi

Senior Equity Analyst at Cantor Fitzgerald

Lee Wazi is a Senior Equity Analyst at Cantor Fitzgerald specializing in healthcare sector research, particularly biopharmaceuticals. Covering companies such as Ascendis Pharma, Replimune Group, Corvus Pharmaceuticals, and Protara Therapeutics, Wazi has made 23 stock recommendations, though their performance metrics include a success rate of approximately 27% and an average return per transaction of -25%, with their most profitable call delivering a 165.5% return. Wazi began their analyst career at Cantor Fitzgerald and has focused on delivering insights into emerging healthcare companies, although their professional credentials and FINRA registration status are not publicly listed. Wazi is noted for in-depth sector specialization and broad equity coverage, but has yet to achieve major industry recognition or top performance rankings.